Compare Autodesk Inc (ADSK) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Autodesk Inc vs Mesoblast Limited — how do they compare? Autodesk Inc trades at $249 (market cap $53.12B), while Mesoblast Limited trades at $16.74 (market cap $2.21B). The key difference: Autodesk Inc is far larger — about 24× Mesoblast Limited's market cap. Which is the better fit depends on your goals.
| ADSK | MESO | |
|---|---|---|
Market Cap | $53.12B | $2.21B |
Sector | Technology | Technology |
52-Week High | $326.79 | $20.96 |
52-Week Low | $187.72 | $12.88 |
Enterprise Value | $52.92B | $2.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Autodesk (ADSK) trades at $249.55, down 2.55% today, but maintains a strong fundamental profile with robust earnings beats, including Q1 2026 EPS of $2.99 versus $2.84 expected. The stock exhibits a bullish technical trend with moving averages supporting upside, though RSI levels indicate potential overbought conditions. Revenue growth is steady, projected to reach $7.5B in 2026, with a high net income margin of 19.49% in 2025.
The outlook remains positive given analyst consensus favoring Buy ratings (74.51%) and a $302.23 price target, implying significant upside. Key risks include competitive pressures in design software and reliance on enterprise spending cycles. Continued execution on AI investments and margin expansion are critical for sustaining valuation multiples.
MESO trades at $16.82, up 0.84% with bullish technical signals from moving averages. The company shows strong revenue growth with Ryoncil generating $115M in its first year, but remains unprofitable with a -144.33% net income margin. Recent developments include positive Phase 3 trial progress and BLA filing for heart failure treatment, supported by analyst consensus leaning bullish with 45% buy ratings.
MESO presents a high-risk, high-reward opportunity with promising commercial traction offset by significant losses. Investment thesis hinges on successful pipeline development and profitability turnaround, while risks include clinical trial outcomes, regulatory approvals, and sustained cash burn requiring careful monitoring of execution milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Autodesk Inc
Founded in 1982, Autodesk is an application software company that serves industries in architecture, engineering, and construction.
Read more on ADSK →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
